MANSFIELD, MA—Earlier this year, clinical research organization Precision for Medicine launched a new U.S. biospecimen collection center in Mansfield, Massachusetts. This week, the expanded apheresis unit collected its first Leukopak, an essential resource for advanced research. Designed to support custom biospecimen collection and lab services for Precision’s clients globally, the center collects clinical and research-grade leukopaks, mobilized or non-mobilized from healthy and diseased subjects, including oncology donors.
The center is FDA-licensed for blood products, GMP/GLP-compliant, CLIA and CAP registered. It also delivers to precise standards, ensuring optimal cell yield, viability, and quality. Collections are initiated within 2-14 days of receipt of purchase order and are often delivered the same or next day.
The Mansfield center joins Precision’s global biospecimen and biomarker services. With 25 million biospecimens managed across 7 CAP-, CLIA-, ISO-, and FDA-registered labs, this comprehensive resource for diagnostic and therapeutic research and development has supported more than 500 trials.
Precision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences. This convergence of trials, labs and data sciences is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine group with over 2,500 people in 35 locations in the U.S., Canada, and Europe.
We’re helping our clients solve the most complex issues in research and development. Let us connect you with the right expert to help your work advance. For more information, visit https://www.precisionformedicine.com.